Literature DB >> 25835969

Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.

Seyed Mohammad Ali Hosseini Rad1, Lida Langroudi, Fatemeh Kouhkan, Laleh Yazdani, Alireza Nouri Koupaee, Sara Asgharpour, Zahra Shojaei, Taravat Bamdad, Ehsan Arefian.   

Abstract

Gene therapy as a therapeutic approach has been the dream for many scientists around the globe. Many strategies have been proposed and applied for this purpose, yet the void for a functional safe method is still apparent. Since most of the diseases are caused by undesirable upregulation (oncogenes) or downregulation (tumor suppressor genes) of genes, major gene therapy's techniques affect gene expression. Most of the methods are used in post-transcriptional level such as RNA inhibitory (RNAi) and splice-switching oligonucleotides (SSOs). RNAi blocks messenger RNA (mRNA) translation by mRNA degradation or interruption between attachments of mRNA with ribosomes' subunits. However, one of the novel methods is the usage of transcription factor targeted decoys. DNA decoys are the new generation of functional gene downregulatory oligonucleotides which compete with specific binding sites of transcription factors. Considering the exponential growth of this technique in both in vitro and in vivo studies, in this paper, we aim to line out the description, design, and application of decoys in research and therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25835969     DOI: 10.1007/s13277-015-3344-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  57 in total

1.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.

Authors:  C Wahlestedt; P Salmi; L Good; J Kela; T Johnsson; T Hökfelt; C Broberger; F Porreca; J Lai; K Ren; M Ossipov; A Koshkin; N Jakobsen; J Skouv; H Oerum; M H Jacobsen; J Wengel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter.

Authors:  C Mischiati; M Borgatti; N Bianchi; C Rutigliano; M Tomassetti; G Feriotto; R Gambari
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

3.  Blockage of STAT3 signaling pathway with a decoy oligodeoxynucleotide inhibits growth of human ovarian cancer cells.

Authors:  Ming Liu; Fei Wang; Zeqing Wen; Min Shi; Hui Zhang
Journal:  Cancer Invest       Date:  2013-12-14       Impact factor: 2.176

4.  Chromatin immunoprecipitation (ChIP).

Authors:  Michael F Carey; Craig L Peterson; Stephen T Smale
Journal:  Cold Spring Harb Protoc       Date:  2009-09

5.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

6.  HIF-1α decoy oligodeoxynucleotides inhibit HIF-1α signaling and breast cancer proliferation.

Authors:  Xuhong Zhu; Qin Li; Shuang Li; Bote Chen; Haidong Zou
Journal:  Int J Oncol       Date:  2014-10-21       Impact factor: 5.650

Review 7.  Adeno-associated virus-mediated cancer gene therapy: current status.

Authors:  Jingfeng Luo; Yuxuan Luo; Jihong Sun; Yurong Zhou; Yajing Zhang; Xiaoming Yang
Journal:  Cancer Lett       Date:  2014-11-10       Impact factor: 8.679

Review 8.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Authors:  Naruya Tomita; Naoki Kashihara; Ryuichi Morishita
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

9.  E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells.

Authors:  Jong Deok Ahn; Cheorl-Ho Kim; Junji Magae; Young Ho Kim; Hye Jin Kim; Kwan-Kyu Park; SaHyun Hong; Keun-Gyu Park; In Kyu Lee; Young-Chae Chang
Journal:  Biochem Biophys Res Commun       Date:  2003-10-31       Impact factor: 3.575

10.  TRED: a transcriptional regulatory element database, new entries and other development.

Authors:  C Jiang; Z Xuan; F Zhao; M Q Zhang
Journal:  Nucleic Acids Res       Date:  2007-01       Impact factor: 16.971

View more
  10 in total

1.  MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs.

Authors:  Mina Soufi-Zomorrod; Abbas Hajifathali; Fatemeh Kouhkan; Mahshid Mehdizadeh; Seyed Mohammad Ali Hosseini Rad; Masoud Soleimani
Journal:  Tumour Biol       Date:  2016-01-20

2.  Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer.

Authors:  Joseph Carmicheal; Sukhwinder Kaur; Surinder K Batra; Apar Kishor Ganti
Journal:  Transl Lung Cancer Res       Date:  2018-09

Review 3.  NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases.

Authors:  T-H Lin; J Pajarinen; L Lu; A Nabeshima; L A Cordova; Z Yao; S B Goodman
Journal:  Adv Protein Chem Struct Biol       Date:  2016-12-09       Impact factor: 3.507

4.  From Influenza Virus Infections to Lupus: Synchronous Estrogen Receptor α and RNA Polymerase II Binding Within the Immunoglobulin Heavy Chain Locus.

Authors:  Bart G Jones; Robert E Sealy; Rhiannon R Penkert; Sherri L Surman; Barbara K Birshtein; Beisi Xu; Geoffrey Neale; Robert W Maul; Patricia J Gearhart; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-02-27       Impact factor: 2.257

Review 5.  Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer.

Authors:  Shreyasi Maity; Rishyani Mukherjee; Satarupa Banerjee
Journal:  Mol Biotechnol       Date:  2022-08-23       Impact factor: 2.860

Review 6.  Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis.

Authors:  Maryam Mahjoubin-Tehran; Yong Teng; Amin Jalili; Seyed Hamid Aghaee-Bakhtiari; Alexander M Markin; Amirhossein Sahebkar
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  Over-expression of NOTCH1 as a biomarker for invasive breast ductal carcinoma.

Authors:  Mahdi Paryan; Rezvan Tavakoli; Seyed Mohammad Ali Hosseini Rad; Neda Feizi; Fereshteh Kamani; Ehsan Mostafavi; Samira Mohammadi-Yeganeh
Journal:  3 Biotech       Date:  2016-02-13       Impact factor: 2.406

8.  Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.

Authors:  George E Naoum; Zeng B Zhu; Donald J Buchsbaum; David T Curiel; Waleed O Arafat
Journal:  Clin Transl Med       Date:  2017-03-01

9.  Lysosome-associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer.

Authors:  Yue-Nan Huang; Xin Guo; Liu-Ping You; Chun-Jing Wang; Jia-Qi Liu; Yun-Long Li
Journal:  Oncol Lett       Date:  2017-09-06       Impact factor: 2.967

Review 10.  Nuclear Receptors, Ligands and the Mammalian B Cell.

Authors:  Bart G Jones; Rhiannon R Penkert; Sherri L Surman; Robert E Sealy; Julia L Hurwitz
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.